Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Computer Sciences Corporation's (CSC) unit DynPort Vaccine Company (DVC) has secured a $90m follow-on contract to continue supporting the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Subscribe to our email newsletter
The ten-year indefinite delivery/indefinite quantity contract will see DVC and its teaming partners, Quintiles, Health Decisions and WCCT Global, supporting and conducting Phase I clinical trials of infectious disease therapeutics.
The trials are designed to evaluate the safety of investigational therapeutic products being studied by NIAID, and determine pharmacokinetic and pharmacodynamic properties, which will inform appropriate human dosing regimens.
Under the deal, DVC will be responsible for managing the overall program and clinical operations, quality assurance and co-development of protocols and concepts, while its partners will provide clinical research and support services for the implementation and conduct of approved clinical trial protocols.
The trials will include therapeutic candidates and investigational products tested to protect against viral (other than HIV), bacterial, parasitic and fungal pathogens, including NIAID priority biodefense pathogens and emerging and re-emerging infectious diseases.
As part of the existing 2008 NIAID contract, DVC has completed four Phase I trials, while continuing to progress on three others.